Michael R Cook1, Kieron Dunleavy2. 1. Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA. 2. Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA. kmd322@georgetown.edu.
Abstract
PURPOSE OF REVIEW: This review aims to discuss recent advances in elucidating the tumor microenvironment (TME) in B lymphomas and resultant novel therapeutic development. RECENT FINDINGS: While tumor morphology, immunophenotype, and molecular profile are established factors that predict outcome and guide therapy, the prognostic impact of infiltrating, non-tumor cells is now emerging. This is simultaneously facilitating the development of new therapies that target non-tumor cells. The tumor microenvironment (TME) is a complex ecosystem composed of infiltrating cells and byproducts, extracellular matrix, and other non-cellular tissues. In lymphomas, our current understanding of the role of the TME is principally informed by studies in B-cell lineage diseases. As we improve our understanding of lymphoma biology, the importance of the impact of the non-tumor cell microenvironment is becoming more apparent. This lays the foundation for the investigation and development of novel therapies and combination strategies that target non-tumor cells and tumor cell/non-tumor cell interactions.
PURPOSE OF REVIEW: This review aims to discuss recent advances in elucidating the tumor microenvironment (TME) in B lymphomas and resultant novel therapeutic development. RECENT FINDINGS: While tumor morphology, immunophenotype, and molecular profile are established factors that predict outcome and guide therapy, the prognostic impact of infiltrating, non-tumor cells is now emerging. This is simultaneously facilitating the development of new therapies that target non-tumor cells. The tumor microenvironment (TME) is a complex ecosystem composed of infiltrating cells and byproducts, extracellular matrix, and other non-cellular tissues. In lymphomas, our current understanding of the role of the TME is principally informed by studies in B-cell lineage diseases. As we improve our understanding of lymphoma biology, the importance of the impact of the non-tumor cell microenvironment is becoming more apparent. This lays the foundation for the investigation and development of novel therapies and combination strategies that target non-tumor cells and tumor cell/non-tumor cell interactions.
Authors: Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy Journal: Haematologica Date: 2016-05 Impact factor: 9.941
Authors: Wouter J Plattel; Anke van den Berg; Lydia Visser; Anne-Marijn van der Graaf; Jan Pruim; Hans Vos; Bouke Hepkema; Arjan Diepstra; Gustaaf W van Imhoff Journal: Haematologica Date: 2011-11-04 Impact factor: 9.941
Authors: C V Hedvat; E S Jaffe; J Qin; D A Filippa; C Cordon-Cardo; G Tosato; S D Nimer; J Teruya-Feldstein Journal: Mod Pathol Date: 2001-12 Impact factor: 7.842
Authors: Eric D Hsi; Hongli Li; Andrew B Nixon; Heiko Schöder; Nancy L Bartlett; Michael LeBlanc; Sonali Smith; Brad S Kahl; John P Leonard; Andrew M Evens; David W Scott; Lisa M Rimsza; Jonathan W Friedberg Journal: Blood Date: 2019-02-05 Impact factor: 22.113
Authors: Paul Greaves; Andrew Clear; Rita Coutinho; Andrew Wilson; Janet Matthews; Andrew Owen; Milensu Shanyinde; T Andrew Lister; Maria Calaminici; John G Gribben Journal: J Clin Oncol Date: 2012-10-08 Impact factor: 44.544
Authors: Yue Ma; Lydia Visser; Han Roelofsen; Marcel de Vries; Arjan Diepstra; Gustaaf van Imhoff; Tineke van der Wal; Marjan Luinge; Gloria Alvarez-Llamas; Hans Vos; Sibrand Poppema; Roel Vonk; Anke van den Berg Journal: Blood Date: 2007-12-10 Impact factor: 22.113